{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T03:02:39Z","timestamp":1789354959847,"version":"build-2803163510"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02226-9","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:14:00Z","timestamp":1782569640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials"],"prefix":"10.1186","volume":"18","author":[{"given":"Donya","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Sadeghirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Aziz","family":"Rasouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfollah","family":"Saed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2936-5930","authenticated-orcid":false,"given":"Yousef","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2226_CR1","doi-asserted-by":"publisher","first-page":"154838","DOI":"10.1016\/j.metabol.2021.154838","volume":"123","author":"JS Yun","year":"2021","unstructured":"Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. 2021;123:154838.","journal-title":"Metabolism"},{"issue":"Suppl 2","key":"2226_CR2","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/PL00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish NJ, et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14\u201321.","journal-title":"Diabetologia"},{"issue":"12","key":"2226_CR3","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"key":"2226_CR4","doi-asserted-by":"crossref","unstructured":"Das SR et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol, 2020. 76(9): pp. 1117\u20131145.","DOI":"10.1016\/j.jacc.2020.05.037"},{"issue":"1","key":"2226_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type, et al. 2 Diabetes management algorithm\u2009\u2013\u20092020 executive summary. Endocr Pract. 2020;26(1):107\u201339.","journal-title":"Endocr Pract"},{"issue":"Suppl 1","key":"2226_CR6","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jcjd.2017.10.034","volume":"42","author":"L Lipscombe","year":"2018","unstructured":"Lipscombe L, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018;42(Suppl 1):S88\u2013103.","journal-title":"Can J Diabetes"},{"issue":"39","key":"2226_CR7","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035\u201387.","journal-title":"Eur Heart J"},{"issue":"9","key":"2226_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","volume":"60","author":"E Sanchez-Rangel","year":"2017","unstructured":"Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017;60(9):1586\u201393.","journal-title":"Diabetologia"},{"issue":"9131","key":"2226_CR9","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"Effect of intensive","year":"1998","unstructured":"Effect of intensive. blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854\u201365.","journal-title":"Lancet"},{"issue":"1","key":"2226_CR10","first-page":"S52","volume":"39","author":"7","year":"2016","unstructured":"7. Approaches to Glycemic Treatment. Diabetes Care. 2016;39(1):S52\u20139.","journal-title":"Diabetes Care"},{"key":"2226_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2147\/CLEP.S113211","volume":"8","author":"DH Christensen","year":"2016","unstructured":"Christensen DH, Rungby J, Thomsen RW. Nationwide trends in glucose-lowering drug use, Denmark, 1999\u20132014. Clin Epidemiol. 2016;8:381\u20137.","journal-title":"Clin Epidemiol"},{"key":"2226_CR12","doi-asserted-by":"publisher","first-page":"k2693","DOI":"10.1136\/bmj.k2693","volume":"362","author":"A Douros","year":"2018","unstructured":"Douros A, et al. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ. 2018;362:k2693.","journal-title":"BMJ"},{"issue":"5","key":"2226_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1517\/14656566.3.5.529","volume":"3","author":"AG Pittas","year":"2002","unstructured":"Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2002;3(5):529\u201340.","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"2226_CR14","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.2165\/00003495-200363130-00004","volume":"63","author":"M Diamant","year":"2003","unstructured":"Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003;63(13):1373\u2013405.","journal-title":"Drugs"},{"key":"2226_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/14750708.2.1.113","volume":"2","author":"F El-Atat","year":"2005","unstructured":"El-Atat F, et al. An overview of the beneficial cardiovascular effects of thiazolidinediones. Therapy. 2005;2:113\u20139.","journal-title":"Therapy"},{"key":"2226_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060586","author":"AK Singh","year":"2021","unstructured":"Singh AK, Yadav D, Sharma N, Jin JO. Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes. Pharmaceuticals (Basel). 2021 Jun 18;14(6):586. https:\/\/doi.org\/10.3390\/ph14060586","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"2226_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jcjd.2014.01.008","volume":"38","author":"L Yang","year":"2014","unstructured":"Yang L, Yuan J, Zhou Z. Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus. Can J Diabetes. 2014;38(6):473\u20139.","journal-title":"Can J Diabetes"},{"issue":"2","key":"2226_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"key":"2226_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16162965","author":"A Tentolouris","year":"2019","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. Int J Environ Res Public Health. 2019 Aug 17;16(16):2965. https:\/\/doi.org\/10.3390\/ijerph16162965","journal-title":"Int J Environ Res Public Health"},{"key":"2226_CR20","doi-asserted-by":"publisher","unstructured":"Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005613. https:\/\/doi.org\/10.1002\/14651858.CD005613.pub3. Update in: Cochrane Database Syst Rev. 2020 Nov 9;11:CD005613.","DOI":"10.1002\/14651858.CD005613.pub3"},{"key":"2226_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ijcard.2017.12.039","volume":"254","author":"Y Fei","year":"2018","unstructured":"Fei Y, et al. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs. Int J Cardiol. 2018;254:291\u20136.","journal-title":"Int J Cardiol"},{"issue":"6","key":"2226_CR22","doi-asserted-by":"publisher","first-page":"147916412312217","DOI":"10.1177\/14791641231221740","volume":"20","author":"M Evans","year":"2023","unstructured":"Evans M, et al. Cardiovascular and renal outcomes of GLP-1 receptor agonists vs. DPP-4 inhibitors and basal insulin in type 2 diabetes mellitus: A systematic review and meta-analysis. Diab Vasc Dis Res. 2023;20(6):14791641231221740.","journal-title":"Diab Vasc Dis Res"},{"key":"2226_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1653147","volume":"12","author":"S Hu","year":"2025","unstructured":"Hu S, Lan G. Comparative efficacy and safety of antidiabetic agents for post-transplant diabetes mellitus: a network meta-analysis. Front Med. 2025;12:1653147.","journal-title":"Front Med"},{"issue":"8","key":"2226_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2226_CR25","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1111\/dom.15251","volume":"25","author":"M Sohn","year":"2023","unstructured":"Sohn M, Frias JP, Lim S. Cardiovascular efficacy and safety of antidiabetic agents: A network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023;25(12):3560\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2226_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12933-023-02035-8","volume":"22","author":"JY Chen","year":"2023","unstructured":"Chen JY, et al. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis. Cardiovasc Diabetol. 2023;22(1):290.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2226_CR27","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1111\/dom.70010","volume":"27","author":"P Bramlage","year":"2025","unstructured":"Bramlage P, et al. Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis. Diabetes Obes Metab. 2025;27(11):6254\u201363.","journal-title":"Diabetes Obes Metab"},{"key":"2226_CR28","doi-asserted-by":"crossref","unstructured":"Page MJ et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021. 372.","DOI":"10.1136\/bmj.n71"},{"issue":"11","key":"2226_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"2226_CR30","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"3","key":"2226_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jclinepi.2011.04.015","volume":"65","author":"EA Akl","year":"2012","unstructured":"Akl EA, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol. 2012;65(3):262\u20137.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2226_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/1536867X1501500402","volume":"15","author":"A Chaimani","year":"2015","unstructured":"Chaimani A, Salanti G. Visualizing assumptions and results in network meta-analysis: the network graphs package. Stata J. 2015;15(4):905\u201350.","journal-title":"Stata J"},{"issue":"4","key":"2226_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","volume":"15","author":"IR White","year":"2015","unstructured":"White IR. Network meta-analysis. Stata J. 2015;15(4):951\u201385.","journal-title":"Stata J"},{"issue":"10","key":"2226_CR34","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, et al. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10):e76654.","journal-title":"PLoS ONE"},{"issue":"2","key":"2226_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JPT Higgins","year":"2012","unstructured":"Higgins JPT, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi\u2010arm studies. Res synthesis methods. 2012;3(2):98\u2013110.","journal-title":"Res synthesis methods"},{"key":"2226_CR36","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Altman DG. Measuring inconsistency in meta-analyses. 2003.","DOI":"10.1136\/bmj.327.7414.557"},{"issue":"7109","key":"2226_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"20","key":"2226_CR38","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1002\/sim.2380","volume":"25","author":"RM Harbord","year":"2006","unstructured":"Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta\u2010analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443\u201357.","journal-title":"Stat Med"},{"key":"2226_CR39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","volume":"93","author":"R Brignardello-Petersen","year":"2018","unstructured":"Brignardello-Petersen R, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36\u201344.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2226_CR40","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082.","journal-title":"PLoS Med"},{"issue":"9","key":"2226_CR41","doi-asserted-by":"publisher","first-page":"730","DOI":"10.7326\/M19-3601","volume":"173","author":"JW Busse","year":"2020","unstructured":"Busse JW, et al. Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries\u202f: A Systematic Review and Network Meta-analysis of Randomized Trials. Ann Intern Med. 2020;173(9):730\u20138.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2226_CR42","doi-asserted-by":"publisher","first-page":"e056400","DOI":"10.1136\/bmjopen-2021-056400","volume":"12","author":"MR Phillips","year":"2022","unstructured":"Phillips MR, et al. Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open. 2022;12(6):e056400.","journal-title":"BMJ Open"},{"key":"2226_CR43","doi-asserted-by":"publisher","first-page":"m3900","DOI":"10.1136\/bmj.m3900","volume":"371","author":"R Brignardello-Petersen","year":"2020","unstructured":"Brignardello-Petersen R, et al. GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ. 2020;371:m3900.","journal-title":"BMJ"},{"issue":"3","key":"2226_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2337\/dc16-1738","volume":"40","author":"M Abdul-Ghani","year":"2017","unstructured":"Abdul-Ghani M, et al. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal\/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care. 2017;40(3):325\u201331.","journal-title":"Diabetes Care"},{"issue":"8","key":"2226_CR45","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2337\/dc14-0024","volume":"37","author":"B Ahr\u00e9n","year":"2014","unstructured":"Ahr\u00e9n B, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"2226_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1463-1326.2010.01334.x","volume":"13","author":"R Arechavaleta","year":"2011","unstructured":"Arechavaleta R, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2226_CR47","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2337\/dc12-1365","volume":"36","author":"JC Arjona Ferreira","year":"2013","unstructured":"Arjona Ferreira JC, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36(5):1067\u201373.","journal-title":"Diabetes Care"},{"issue":"1","key":"2226_CR48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","volume":"23","author":"F Attaran","year":"2023","unstructured":"Attaran F, et al. Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial. BMC Gastroenterol. 2023;23(1):327.","journal-title":"BMC Gastroenterol"},{"key":"2226_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"CJ Bailey","year":"2013","unstructured":"Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.","journal-title":"BMC Med"},{"issue":"4","key":"2226_CR50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"CJ Bailey","year":"2015","unstructured":"Bailey CJ, et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med. 2015;32(4):531\u201341.","journal-title":"Diabet Med"},{"issue":"12","key":"2226_CR51","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/dom.12736","volume":"18","author":"TS Bailey","year":"2016","unstructured":"Bailey TS, et al. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial. Diabetes Obes Metab. 2016;18(12):1191\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2226_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12872-023-03549-5","volume":"23","author":"W Barbour","year":"2023","unstructured":"Barbour W, et al. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial. BMC Cardiovasc Disord. 2023;23(1):557.","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"2226_CR53","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s40261-013-0107-8","volume":"33","author":"AH Barnett","year":"2013","unstructured":"Barnett AH, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33(10):707\u201317.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"2226_CR54","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9739","key":"2226_CR55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431\u20139.","journal-title":"Lancet"},{"issue":"2","key":"2226_CR56","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"2226_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"3","key":"2226_CR58","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/dom.12428","volume":"17","author":"B Bode","year":"2015","unstructured":"Bode B, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. Diabetes Obes Metab. 2015;17(3):294\u2013303.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2226_CR59","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1463-1326.2008.01023.x","volume":"11","author":"G Bolli","year":"2009","unstructured":"Bolli G, et al. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11(6):589\u201395.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2226_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/dme.12328","volume":"31","author":"GB Bolli","year":"2014","unstructured":"Bolli GB, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med. 2014;31(2):176\u201384.","journal-title":"Diabet Med"},{"issue":"4","key":"2226_CR61","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2337\/dc06-1732","volume":"30","author":"E Bosi","year":"2007","unstructured":"Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30(4):890\u20135.","journal-title":"Diabetes Care"},{"issue":"12","key":"2226_CR62","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1463-1326.2011.01463.x","volume":"13","author":"E Bosi","year":"2011","unstructured":"Bosi E, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088\u201396.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2226_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","volume":"154","author":"JB Buse","year":"2011","unstructured":"Buse JB, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103\u201312.","journal-title":"Ann Intern Med"},{"issue":"11","key":"2226_CR64","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.2337\/dc14-0785","volume":"37","author":"JB Buse","year":"2014","unstructured":"Buse JB, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926\u201333.","journal-title":"Diabetes Care"},{"issue":"15","key":"2226_CR65","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"7","key":"2226_CR66","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","volume":"38","author":"WT Cefalu","year":"2015","unstructured":"Cefalu WT, et al. Dapagliflozin\u2019s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 2015;38(7):1218\u201327.","journal-title":"Diabetes Care"},{"issue":"2","key":"2226_CR67","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1479164111404574","volume":"8","author":"AR Chacra","year":"2011","unstructured":"Chacra AR, et al. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8(2):150\u20139.","journal-title":"Diab Vasc Dis Res"},{"issue":"9","key":"2226_CR68","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1463-1326.2009.01055.x","volume":"11","author":"G Charpentier","year":"2009","unstructured":"Charpentier G, Halimi S. Earlier triple therapy with pioglitazone in patients with type 2 diabetes. Diabetes Obes Metab. 2009;11(9):844\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR69","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1111\/dom.13340","volume":"20","author":"YH Chen","year":"2018","unstructured":"Chen YH, et al. Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial. Diabetes Obes Metab. 2018;20(9):2121\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"10278","key":"2226_CR70","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, et al. Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"2","key":"2226_CR71","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dc14-2883","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016;39(2):222\u201330.","journal-title":"Diabetes Care"},{"issue":"7","key":"2226_CR72","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687\u201399.","journal-title":"JAMA"},{"issue":"9","key":"2226_CR73","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2337\/dc08-1984","volume":"32","author":"RA DeFronzo","year":"2009","unstructured":"DeFronzo RA, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649\u201355.","journal-title":"Diabetes Care"},{"issue":"12","key":"2226_CR74","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/dom.12377","volume":"16","author":"S Del Prato","year":"2014","unstructured":"Del Prato S, et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"9493","key":"2226_CR75","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279\u201389.","journal-title":"Lancet"},{"issue":"2","key":"2226_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"4","key":"2226_CR77","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","volume":"64","author":"KC Ferdinand","year":"2014","unstructured":"Ferdinand KC, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731\u20137.","journal-title":"Hypertension"},{"issue":"2","key":"2226_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","volume":"11","author":"E Ferrannini","year":"2009","unstructured":"Ferrannini E, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2226_CR79","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(12):1004\u201316.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9840","key":"2226_CR80","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","volume":"380","author":"B Gallwitz","year":"2012","unstructured":"Gallwitz B, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475\u201383.","journal-title":"Lancet"},{"issue":"1","key":"2226_CR81","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12933-017-0593-8","volume":"16","author":"I Gantz","year":"2017","unstructured":"Gantz I, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2017;16(1):112.","journal-title":"Cardiovasc Diabetol"},{"issue":"10193","key":"2226_CR82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"24","key":"2226_CR83","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"10","key":"2226_CR84","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"3","key":"2226_CR85","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1751-7133.2010.00154.x","volume":"16","author":"TD Giles","year":"2010","unstructured":"Giles TD, et al. Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease. Congest Heart Fail. 2010;16(3):111\u20137.","journal-title":"Congest Heart Fail"},{"issue":"6","key":"2226_CR86","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cardfail.2008.02.007","volume":"14","author":"TD Giles","year":"2008","unstructured":"Giles TD, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14(6):445\u201352.","journal-title":"J Card Fail"},{"issue":"4","key":"2226_CR87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/ijcp.12119","volume":"67","author":"B G\u00f6ke","year":"2013","unstructured":"G\u00f6ke B, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307\u201316.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"2226_CR88","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1055\/s-0028-1082334","volume":"40","author":"B G\u00f6ke","year":"2008","unstructured":"G\u00f6ke B, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-na\u00efve patients with type 2 diabetes: comparison with metformin. Horm Metab Res. 2008;40(12):892\u20135.","journal-title":"Horm Metab Res"},{"issue":"3","key":"2226_CR89","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"2226_CR90","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/dom.13266","volume":"20","author":"C Guja","year":"2018","unstructured":"Guja C, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes Obes Metab. 2018;20(7):1602\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2226_CR91","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.diabres.2015.05.044","volume":"110","author":"HU Haering","year":"2015","unstructured":"Haering HU, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110(1):82\u201390.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"2226_CR92","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/03007995.2017.1335638","volume":"33","author":"Y Handelsman","year":"2017","unstructured":"Handelsman Y, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017;33(10):1861\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2226_CR93","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/dom.12194","volume":"16","author":"RR Henry","year":"2014","unstructured":"Henry RR, et al. Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone\u2013a factorial study. Diabetes Obes Metab. 2014;16(3):223\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"10157","key":"2226_CR94","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"8","key":"2226_CR95","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/03007995.2019.1583450","volume":"35","author":"P Hollander","year":"2019","unstructured":"Hollander P, et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019;35(8):1335\u201343.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"2226_CR96","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/1479164111404575","volume":"8","author":"PL Hollander","year":"2011","unstructured":"Hollander PL, et al. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8(2):125\u201335.","journal-title":"Diab Vasc Dis Res"},{"issue":"13","key":"2226_CR97","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"2226_CR98","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/dom.12414","volume":"17","author":"PD Home","year":"2015","unstructured":"Home PD, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17(2):179\u201387.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2226_CR99","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","volume":"36","author":"J Hong","year":"2013","unstructured":"Hong J, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304\u201311.","journal-title":"Diabetes Care"},{"issue":"9","key":"2226_CR100","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"2226_CR101","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1592\/phco.26.10.1388","volume":"26","author":"R Jain","year":"2006","unstructured":"Jain R, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388\u201395.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2226_CR102","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/dom.14232","volume":"23","author":"L Ji","year":"2021","unstructured":"Ji L, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021;23(2):404\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR103","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/dom.13352","volume":"20","author":"R Kawamori","year":"2018","unstructured":"Kawamori R, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018;20(9):2200\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2226_CR104","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962\u201371.","journal-title":"Kidney Int"},{"issue":"8","key":"2226_CR105","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","volume":"37","author":"CS Kovacs","year":"2015","unstructured":"Kovacs CS, et al. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. Clin Ther. 2015;37(8):1773-88.e1.","journal-title":"Clin Ther"},{"issue":"2","key":"2226_CR106","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.2337\/dc14-1684","volume":"38","author":"M Laakso","year":"2015","unstructured":"Laakso M, et al. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38(2):e15-7.","journal-title":"Diabetes Care"},{"issue":"10","key":"2226_CR107","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2337\/dc13-2855","volume":"37","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37(10):2723\u201330.","journal-title":"Diabetes Care"},{"issue":"7","key":"2226_CR108","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"LA Leiter","year":"2014","unstructured":"Leiter LA, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62(7):1252\u201362.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"2226_CR109","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355\u201364.","journal-title":"Diabetes Care"},{"issue":"3","key":"2226_CR110","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2337\/dc14-2365","volume":"38","author":"A Lewin","year":"2015","unstructured":"Lewin A, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394\u2013402.","journal-title":"Diabetes Care"},{"issue":"16","key":"2226_CR111","doi-asserted-by":"publisher","first-page":"e025045","DOI":"10.1161\/JAHA.121.025045","volume":"11","author":"JW Li","year":"2022","unstructured":"Li JW, et al. Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. J Am Heart Assoc. 2022;11(16):e025045.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"2226_CR112","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"2226_CR113","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"2226_CR114","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"11","key":"2226_CR115","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/dom.12737","volume":"18","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11):1134\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR116","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1463-1326.2010.01233.x","volume":"12","author":"DR Matthews","year":"2010","unstructured":"Matthews DR, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"10208","key":"2226_CR117","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","volume":"394","author":"DR Matthews","year":"2019","unstructured":"Matthews DR, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519\u201329.","journal-title":"Lancet"},{"issue":"21","key":"2226_CR118","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572\u201381.","journal-title":"JAMA"},{"issue":"4","key":"2226_CR119","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2337\/dc16-2143","volume":"40","author":"GS Meneilly","year":"2017","unstructured":"Meneilly GS, et al. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 2017;40(4):485\u201393.","journal-title":"Diabetes Care"},{"issue":"12","key":"2226_CR120","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/dme.12814","volume":"32","author":"L Merker","year":"2015","unstructured":"Merker L, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med. 2015;32(12):1555\u201367.","journal-title":"Diabet Med"},{"issue":"5","key":"2226_CR121","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1753-0407.12351","volume":"8","author":"RG Moses","year":"2016","unstructured":"Moses RG, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8(5):701\u201311.","journal-title":"J Diabetes"},{"issue":"11","key":"2226_CR122","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1111\/dom.13437","volume":"20","author":"D M\u00fcller-Wieland","year":"2018","unstructured":"M\u00fcller-Wieland D, et al. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(11):2598\u2013607.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2226_CR123","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1177\/1479164116639229","volume":"13","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, et al. Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial. Diab Vasc Dis Res. 2016;13(4):286\u201398.","journal-title":"Diab Vasc Dis Res"},{"issue":"21","key":"2226_CR124","first-page":"2099","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(21):2099.","journal-title":"N Engl J Med"},{"issue":"13","key":"2226_CR125","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561\u201373.","journal-title":"JAMA"},{"issue":"9","key":"2226_CR126","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1463-1326.2011.01416.x","volume":"13","author":"L Olansky","year":"2011","unstructured":"Olansky L, et al. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents. Diabetes Obes Metab. 2011;13(9):841\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"2226_CR127","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"issue":"12","key":"2226_CR128","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1751-7176.2010.00389.x","volume":"12","author":"A Perez","year":"2010","unstructured":"Perez A, et al. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2010;12(12):973\u201382.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"24","key":"2226_CR129","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"23","key":"2226_CR130","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"6","key":"2226_CR131","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1463-1326.2011.01385.x","volume":"13","author":"A Pf\u00fctzner","year":"2011","unstructured":"Pf\u00fctzner A, et al. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13(6):567\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2226_CR132","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/dom.12121","volume":"15","author":"M Pinget","year":"2013","unstructured":"Pinget M, et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2226_CR133","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/dom.12937","volume":"19","author":"P Pozzilli","year":"2017","unstructured":"Pozzilli P, et al. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab. 2017;19(7):1024\u201331.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2226_CR134","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"2226_CR135","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","volume":"84","author":"RE Pratley","year":"2024","unstructured":"Pratley RE, et al. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. J Am Coll Cardiol. 2024;84(17):1615\u201328.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2226_CR136","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/dom.12382","volume":"16","author":"J Reusch","year":"2014","unstructured":"Reusch J, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16(12):1257\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2226_CR137","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1111\/dom.13457","volume":"20","author":"M Ridderstr\u00e5le","year":"2018","unstructured":"Ridderstr\u00e5le M, et al. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes Obes Metab. 2018;20(12):2768\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR138","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.2337\/dc12-2454","volume":"36","author":"MC Riddle","year":"2013","unstructured":"Riddle MC, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489\u201396.","journal-title":"Diabetes Care"},{"issue":"9","key":"2226_CR139","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.2337\/dc12-2462","volume":"36","author":"MC Riddle","year":"2013","unstructured":"Riddle MC, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497\u2013503.","journal-title":"Diabetes Care"},{"issue":"2","key":"2226_CR140","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/dme.13256","volume":"34","author":"HW Rodbard","year":"2017","unstructured":"Rodbard HW, et al. Safety and efficacy of insulin degludec\/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-na\u00efve people with Type 2 diabetes: the DUAL IV trial. Diabet Med. 2017;34(2):189\u201396.","journal-title":"Diabet Med"},{"key":"2226_CR141","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.","journal-title":"Cardiovasc Diabetol"},{"issue":"15","key":"2226_CR142","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"3","key":"2226_CR143","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","volume":"28","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complicat. 2014;28(3):386\u201392.","journal-title":"J Diabetes Complicat"},{"issue":"7","key":"2226_CR144","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815\u201323.","journal-title":"Diabetes Care"},{"issue":"10","key":"2226_CR145","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2226_CR146","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"1","key":"2226_CR147","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"9","key":"2226_CR148","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/dom.13795","volume":"21","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, et al. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(9):2152\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2226_CR149","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/dom.12102","volume":"15","author":"J Rosenstock","year":"2013","unstructured":"Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2226_CR150","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"D Russell-Jones","year":"2012","unstructured":"Russell-Jones D, et al. Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4). Diabetes Care. 2012;35(2):252\u20138.","journal-title":"Diabetes Care"},{"issue":"7","key":"2226_CR151","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/dom.12461","volume":"17","author":"G Schernthaner","year":"2015","unstructured":"Schernthaner G, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015;17(7):630\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR152","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.2337\/dc12-2491","volume":"36","author":"G Schernthaner","year":"2013","unstructured":"Schernthaner G, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36(9):2508\u201315.","journal-title":"Diabetes Care"},{"issue":"8","key":"2226_CR153","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1463-1326.2009.01051.x","volume":"11","author":"A Schweizer","year":"2009","unstructured":"Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"2226_CR154","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"12","key":"2226_CR155","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/dom.13473","volume":"20","author":"R Scott","year":"2018","unstructured":"Scott R, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2226_CR156","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1742-1241.2010.02353.x","volume":"64","author":"T Seck","year":"2010","unstructured":"Seck T, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562\u201376.","journal-title":"Int J Clin Pract"},{"issue":"12","key":"2226_CR157","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1055\/s-0035-1549875","volume":"47","author":"Y Seino","year":"2015","unstructured":"Seino Y, et al. Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin\u00b1Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study. Horm Metab Res. 2015;47(12):895\u2013900.","journal-title":"Horm Metab Res"},{"issue":"4","key":"2226_CR158","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/jdi.12457","volume":"7","author":"Y Seino","year":"2016","unstructured":"Seino Y, et al. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial. J Diabetes Investig. 2016;7(4):565\u201373.","journal-title":"J Diabetes Investig"},{"issue":"5","key":"2226_CR159","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1185\/03007991003672551","volume":"26","author":"Y Seino","year":"2010","unstructured":"Seino Y, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010;26(5):1013\u201322.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2226_CR160","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2226_CR161","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s13300-014-0072-0","volume":"5","author":"K Strojek","year":"2014","unstructured":"Strojek K, et al. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5(1):267\u201383.","journal-title":"Diabetes Ther"},{"issue":"2","key":"2226_CR162","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ehjcvp\/pvac059","volume":"9","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, et al. Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):165\u201372.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"2226_CR163","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2165\/11316510-000000000-00000","volume":"32","author":"KG Tolman","year":"2009","unstructured":"Tolman KG, et al. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32(9):787\u2013800.","journal-title":"Drug Saf"},{"issue":"8","key":"2226_CR164","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2337\/dc13-2759","volume":"37","author":"G Umpierrez","year":"2014","unstructured":"Umpierrez G, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37(8):2168\u201376.","journal-title":"Diabetes Care"},{"issue":"3","key":"2226_CR165","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"5","key":"2226_CR166","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1463-1326.2011.01530.x","volume":"14","author":"J Wainstein","year":"2012","unstructured":"Wainstein J, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(5):409\u201318.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2226_CR167","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/dom.12479","volume":"17","author":"RS Weinstock","year":"2015","unstructured":"Weinstock RS, et al. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. Diabetes Obes Metab. 2015;17(9):849\u201358.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"2226_CR168","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"6","key":"2226_CR169","doi-asserted-by":"publisher","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","volume":"156","author":"JP Wilding","year":"2012","unstructured":"Wilding JP, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405\u201315.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2226_CR170","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"2226_CR171","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/joim.12293","volume":"277","author":"W Xu","year":"2015","unstructured":"Xu W, et al. Comparison of the effects on glycaemic control and \u03b2-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). J Intern Med. 2015;277(1):137\u201350.","journal-title":"J Intern Med"},{"issue":"10","key":"2226_CR172","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","volume":"16","author":"JF Yale","year":"2014","unstructured":"Yale JF, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16(10):1016\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2226_CR173","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1753-0407.12634","volume":"10","author":"W Yang","year":"2018","unstructured":"Yang W, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. J Diabetes. 2018;10(7):589\u201399.","journal-title":"J Diabetes"},{"issue":"8","key":"2226_CR174","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/dmrr.2541","volume":"30","author":"C Yu Pan","year":"2014","unstructured":"Yu Pan C, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev. 2014;30(8):726\u201335.","journal-title":"Diabetes Metab Res Rev"},{"issue":"12","key":"2226_CR175","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"issue":"22","key":"2226_CR176","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"2226_CR177","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"key":"2226_CR178","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","volume":"372","author":"SC Palmer","year":"2021","unstructured":"Palmer SC, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573.","journal-title":"BMJ"},{"issue":"10166","key":"2226_CR179","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"key":"2226_CR180","doi-asserted-by":"publisher","first-page":"b4909","DOI":"10.1136\/bmj.b4909","volume":"340","author":"DE Bonds","year":"2010","unstructured":"Bonds DE, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.","journal-title":"BMJ"},{"issue":"1","key":"2226_CR181","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12933-019-0909-y","volume":"18","author":"JS Yun","year":"2019","unstructured":"Yun JS, et al. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. 2019;18(1):103.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2226_CR182","doi-asserted-by":"publisher","first-page":"e002875","DOI":"10.1161\/JAHA.115.002875","volume":"5","author":"A Goto","year":"2016","unstructured":"Goto A, et al. Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc. 2016;5(3):e002875.","journal-title":"J Am Heart Assoc"},{"key":"2226_CR183","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","volume":"60","author":"SJ Griffin","year":"2017","unstructured":"Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60:1620\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"2226_CR184","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc23-Sint","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, et al. Introduction and Methodology: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S1\u20134.","journal-title":"Diabetes Care"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02226-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02226-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:02:41Z","timestamp":1789351361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02226-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":184,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2226"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02226-9","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the Ethics Committee of Kurdistan University of Medical Sciences.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"203"}}